Danet Guénahel H, Pan Yi, Luongo Jennifer L, Bonnet Dominique A, Simon M Celeste
Division of Hematology-Oncology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104-6160, USA.
J Clin Invest. 2003 Jul;112(1):126-35. doi: 10.1172/JCI17669.
It has been proposed that bone marrow (BM) hematopoietic stem and progenitor cells are distributed along an oxygen (O2) gradient, where stem cells reside in the most hypoxic areas and proliferating progenitors are found in O2-rich areas. However, the effects of hypoxia on human hematopoietic stem cells (HSCs) have not been characterized. Our objective was to evaluate the functional and molecular responses of human BM progenitors and stem cells to hypoxic conditions. BM lineage-negative (Lin-) CD34+CD38- cells were cultured in serum-free medium under 1.5% O2 (hypoxia) or 20% O2 (normoxia) for 4 days. Using limiting dilution analysis, we demonstrate that the absolute number of SCID-repopulating cells (SRCs) increased by 5.8-fold in hypoxic cultures compared with normoxia, and by 4.2-fold compared with freshly isolated Lin-CD34+CD38- cells. The observed increase in BM-repopulating activity was associated with a preferential expansion of Lin-CD34+CD38- cells. We also demonstrate that, in response to hypoxia, hypoxia-inducible factor-1alpha protein was stabilized, surface expression of angiogenic receptors was upregulated, and VEGF secretion increased in BM Lin-CD34+ cultures. The use of low O2 levels to enhance the survival and/or self-renewal of human BM HSCs in vitro represents an important advance and could have valuable clinical implications.
有人提出,骨髓(BM)造血干细胞和祖细胞沿氧(O2)梯度分布,其中干细胞位于氧含量最低的区域,而增殖祖细胞则存在于富氧区域。然而,缺氧对人类造血干细胞(HSCs)的影响尚未得到明确描述。我们的目的是评估人类BM祖细胞和干细胞对缺氧条件的功能和分子反应。将BM谱系阴性(Lin-)CD34 + CD38-细胞在无血清培养基中于1.5% O2(缺氧)或20% O2(常氧)条件下培养4天。通过极限稀释分析,我们证明与常氧培养相比,缺氧培养中严重联合免疫缺陷(SCID)重建细胞(SRCs)的绝对数量增加了5.8倍,与新鲜分离的Lin-CD34 + CD38-细胞相比增加了4.2倍。观察到的BM重建活性增加与Lin-CD34 + CD38-细胞的优先扩增有关。我们还证明,在缺氧反应中,缺氧诱导因子-1α蛋白稳定,BM Lin-CD34 +培养物中血管生成受体的表面表达上调,VEGF分泌增加。利用低氧水平在体外增强人类BM HSCs的存活和/或自我更新是一项重要进展,可能具有重要的临床意义。
J Clin Invest. 2003-7
Cytotherapy. 2003
Proc Natl Acad Sci U S A. 2002-8-6
J Exp Clin Cancer Res. 2025-8-14
Stem Cells Transl Med. 2023-10-5
Stem Cell Investig. 2023-7-11
Front Bioeng Biotechnol. 2023-5-9
PLoS Comput Biol. 2023-1
Front Oncol. 2022-8-18
Genes Dev. 2002-6-15
Nat Rev Cancer. 2002-1
Blood. 2002-1-1